RCS - Creo Medical Group - SpydrBlade™ Flex used in novel BEAM procedures

Creo MedicalAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260505:nRSE9425Ca&default-theme=true

RNS Number : 9425C  Creo Medical Group PLC  05 May 2026

 

Creo Medical Group plc

("Creo", the "Company" or the "Group")

 

Creo Medical's SpydrBlade™ Flex used in novel bariatric endoscopic technique

by leading US innovator

 

Creo Medical Group plc ("Creo" or the "Group"), the medical device company
specialising in advanced energy solutions for therapeutic endoscopy, today
announces the clinical use of SpydrBlade Flex in Bariatric Endoscopic Antral
Myotomy ("BEAM") procedures, performed by Professor Christopher C. Thompson
MD, a globally recognised pioneer in bariatric endoscopy and originator of the
BEAM technique.

 

Professor Thompson successfully completed two BEAM procedures using SpydrBlade
Flex and presented the results at Frontiers in Endoscopic Surgery (FES) 2026,
a leading international forum for advanced and emerging endoscopic procedures.

 

Translating innovation from podium to practice

BEAM is a non-invasive endoscopic bariatric procedure that adapts principles
from third-space endoscopy to selectively target the gastric antrum, reducing
contractility and delaying gastric emptying to promote long term satiety and
weight loss in obese patients.

 

The use of SpydrBlade Flex for BEAM procedures highlights the rapid evolution
of endoscopic bariatric techniques and the capability of Creo's products to
deliver precision and control in complex submucosal environments.

 

In the procedures, SpydrBlade Flex was utilised to perform a precise full
thickness antral myotomy, demonstrating its versatility across advanced
third-space and bariatric endoscopic procedures.

 

Expanding the role of advanced energy in metabolic endoscopy

SpydrBlade Flex is powered by Creo's CROMA™ Advanced Energy Platform,
delivering adaptive bipolar radiofrequency and microwave energy to enable
controlled cutting, dissection and haemostasis.

 

Endoscopic bariatric therapies such as BEAM are increasingly positioned as a
minimally invasive option between pharmacological therapies and surgical
intervention. As the field evolves towards approaches that modulate
physiological function, advanced energy solutions are expected to play a
central role in enabling safe and reproducible procedures.

 

Supporting global clinical leadership

Creo continues to collaborate with leading clinical innovators and centres of
excellence to support the development and adoption of advanced endoscopic
techniques.

 

Successful use of SpydrBlade Flex in BEAM further reinforces its role as a
core component of Creo's advanced GI portfolio, with the potential to support
adoption across both established and emerging therapeutic endoscopy
procedures.

 

Professor Thompson said: "BEAM represents a new direction in bariatric
endoscopy, focusing on modulation of gastric physiology to achieve weight
loss. The ability to perform precise submucosal dissection and controlled full
thickness myotomy is critical to the success of this approach.

 

"SpydrBlade Flex is a gamechanger for the myotomy and provides a high level of
precision and control during these steps, supporting both the efficiency and
consistency of the procedure.  Before having the SpydrBlade Flex device,
performing full thickness myotomy during the BEAM procedure was daunting.
SpydrBlade Flex offers us more precision, speed, and the ability to safely
perform, teach and potentially democratize this procedure."

 

 

Craig Gulliford, Chief Executive Officer of Creo Medical, said: "The use of
SpydrBlade Flex in BEAM procedures highlights the role our products can play
in enabling the next generation of therapeutic endoscopy.

 

"As new procedural categories emerge, we are focused on ensuring our advanced
energy platform supports clinicians with the precision and flexibility
required to safely adopt and scale these innovations and bring improved
patient outcomes. This further strengthens our strategy of driving platform
utilisation by expanding clinical applications and partnerships with leading
innovators."

 

For further information please contact:

 

 Creo Medical Group plc                                                         www.creomedical.com
                                                                                (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                              Via Walbrook PR

 Deutsche Numis (Nominated Adviser, Joint Broker and Financial Adviser)         +44 (0)20 7260 1000

 Duncan Monteith / Sher Shah

 Shore Capital (Joint Broker)                                                   +44 (0)20 7408 4090

 Daniel Bush / Lucy Bowden

 Walbrook PR Ltd                       Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings         Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABZLLBQELEBBK



            Copyright 2019 Regulatory News Service, all rights reserved